PT  - JOURNAL ARTICLE
AU  - Hoyle, Brian
ED  - Barkhof, Frederik
TI  - Postrelapse MS Treatment with Alemtuzumab Better than SC IFN-β-1a
DP  - 2014 Jul 01
TA  - MD Conference Express
PG  - 14--15
VI  - 14
IP  - 29
4099  - http://mdc.sagepub.com/content/14/29/14.short
4100  - http://mdc.sagepub.com/content/14/29/14.full
AB  - Subgroup analyses, entitled An Extension Protocol for Multiple Sclerosis Patients Who Participated in Genzyme-Sponsored Studies of Alemtuzumab [NCT00930553; Barkhof F et al. ACTRIMS/ECTRIMS 2014 (poster P075)], of an ongoing, open-label extension of the Comparison of Alemtuzumab and Rebif Efficacy in Multiple Sclerosis, Study Two [CARE-MS II; Coles AJ et al. Lancet. 2012], have confirmed the superiority of treatment of MS using the anti-CD52 humanized monoclonal antibody, alemtuzumab, over subcutaneous interferon beta-1a (SC IFN-β-1a) in magnetic resonance imaging (MRI) outcomes.